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Objective. To assess practice pattern similarities and differences amongst pediatric rheumatologists and nephrologists in the
management of pediatric Granulomatosis with Polyangiitis (GPA). Methods. A voluntary survey was distributed to the Midwest
Pediatric Nephrology ConsortiumGroup (MWPNC) and an international pediatric rheumatology email listserv in 2016-2017. Data
were collected on general practice characteristics and preferences for induction management under three clinical scenarios (A-
C): newly diagnosed GPA with glomerulonephritis, GPA with rapidly progressive glomerulonephritis, and GPA with pulmonary
hemorrhage. In addition, individual preferences for GPA maintenance medications, disease monitoring, and management of GPA
with end-stage renal disease were ascertained. Results. There was a 68% response rate from the MWPNC membership and equal
numbers of rheumatology respondents. Survey results revealed Rituximab plus Cyclophosphamide is a more common induction
choice for rheumatologists than nephrologists in induction Scenarios A and B, whereas Cyclophosphamide is more commonly
chosen by nephrologists in Scenario A. Plasmapheresis rates increased for Scenarios A, B, and C for both specialties, but were
overall low. There was no clear consensus on the duration of maintenance therapy nor diagnostic work-up. Rheumatologists more
frequently chose Rituximab for maintenance and induction compared to nephrologists. There was also a higher than expected
proportion of Mycophenolate Mofetil use for both specialties. Conclusion. This survey has revealed important differences in the
way that rheumatologists and nephrologists manage this disease. It highlights the need for well-designed clinical trials in pediatric
GPA patients and reveals that both specialties must be represented during consensus-building and clinical trial design efforts.
1. Introduction
ANCA-associated vasculitis (AAV) is a disease which
includes Granulomatosis with Polyangiitis (GPA) (formerly
known as Wegener Granulomatosis), Microscopic Polyangi-
itis (MPA), and Eosinophilic Granulomatosis with Polyangi-
itis (EoGPA, formerly known as Churg Strauss Syndrome).
Despite the commonality of ANCA association, the epi-
demiology, pathophysiology, course, and prognosis of these
diseases are not uniform [1]. GPA is the most common AAV
and while the incidence is low, it is rising from 0.2 to 1.2
per 100,000 [2], a trend that is consistent with our local
experience.
Themedian age of GPA disease onset in childhood ranges
from 11.7 to 14 years in the European Vasculitis registry
and the international ARCHiVE cohort study, respectively
[1, 3, 4]. In the ARCHiVE registry, 83% of newly diagnosed
pediatric GPA patients presented with glomerulonephritis.
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The care of patients with GPA bridges the expertise of
primarily two subspecialties, rheumatology and nephrology.
It is presumed that current practice patterns of GPA amongst
rheumatologists and nephrologists differ. To date there are
no pediatric nephrology consensus guidelines supporting the
management of the renal involvement of this disease. The
European League Against Rheumatism (EULAR) released
consensus statements in 2009 and updated in 2016 for
AAV management, including recommendations for rapidly
progressive glomerulonephritis (RPGN), pulmonary hem-
orrhage, and organ-threatening complications [5]. However
these recommendations are not pediatric-specific and do not
address management of end-stage renal disease in AAV, and
it is unclear how familiar pediatric nephrologists are with
the recommendations. Prompted by a recent increase in new
pediatric GPA diagnoses in our local practice area and a
lack of consensus guidance, we undertook a comparative
survey to illustrate the practice patterns amongst pediatric
nephrologists and rheumatologists for three different clinical
presentations of pediatric GPA.
Pediatric GPA patients with renal involvement require a
cooperative partnership between pediatric rheumatology and
nephrology to care for the organ-threatening complications
of this vasculitis and for the long-term management of
immunosuppression. The goal of this survey is to identify
commonalities in practice as well as to highlight disparate
practice patterns that reveal specific education needs and
areas that require further research.
2. Methods
This is an international descriptive survey of pediatric
nephrologists and rheumatologists regarding the practice
patterns of GPA.Members of theMidwest Pediatric Nephrol-
ogyConsortium (MWPNC) and those of a pediatric rheuma-
tology email listserv were asked to complete a voluntary
survey on GPA practice patterns. The MWPNC is a collab-
orative clinical and translational research organization with
73 member centers represented across the United States,
PuertoRico, andCanada.Thepediatric rheumatology listserv
has an international email membership termed the “Pedi-
atric Rheumatology Bulletin Board” hosted by McMaster
University. A total of four email solicitations were sent
between October 2016 and April 2017 to both memberships.
Study objectives were presented to MWPNC members at a
biannual research conference during this time period. Survey
data were managed and collected using REDCap electronic
data capture hosted at Virginia Commonwealth University
(REDCap supported by Award Number UL1TR000058 from
the NCRR). The full survey is available in Supplementary
Materials 1 and included 5 sections.
Section 1 identified general characteristics such as the
respondent’s practice setting, the number of pediatric GPA
patients currently followed, and whether their division had
written consensus protocols for either the induction or
maintenance treatment of GPA. In Section 2, respondents
were asked to provide their first-line choice of induction
medications depending on the presentation of a GPA patient
in three different scenarios. They were first asked to con-
sider management choices in a new GPA patient presenting
with glomerulonephritis (Scenario A), a new patient with
rapidly progressive glomerulonephritis (RPGN, Scenario B)
as diagnosed using site-specific criteria, and a new patient
with pulmonary hemorrhage (Scenario C). After induction
differences were ascertained for Scenarios B and C, respon-
dents were instructed to frame their remaining responses
under Scenario A, for a presentation of a new diagnosis GPA
with glomerulonephritis. In Sections 3 and 4, preferences
were ascertained for maintenance Cyclophosphamide versus
Rituximab,maintenanceAzathioprine versusMycophenolate
Mofetil use, Trimethoprim-Sulfamethoxazole use, and clini-
cal tools used for assessing initial and relapse disease activity.
Finally, Section 5 was directed towards understanding the
management of end-stage renal disease, including choice
of dialysis modality, the timing of renal transplant once in
remission, and the preferred choice of transplant immuno-
suppressive medications in GPA.
Multiple group proportions were compared by 𝜒2 anal-
ysis, two sample proportions by Adjusted Wald test, with
statistical significance level alpha <0.05. Statistical analysis
was performed using JMP v.13.
3. Results
3.1. Survey Section 1: General Characteristics. Of the 145
responses to the survey, 7 were incomplete across all sections
and excluded. The remaining 138 responses represented 42
unique rheumatology institutions and 3 unidentified, and
50 unique nephrology institutions and 2 unidentified which
represented 68% of the MWPNC membership. Table 1 lists
practice setting differences and characteristics of the respon-
dents. The primary management responsibility differed by
specialty: 27%of the nephrology respondents (Neph) claimed
they had primary management responsibility, whereas no
rheumatology respondents (Rheum) reported that nephrol-
ogy primarily managed the patients. Seven Rheum and
9 Neph respondents completed Section 1, but failed to
complete Sections 2-5 and were therefore censored from the
remainder of the analysis.
3.2. Survey Section 2: Induction Medications. Respondents
were asked to select their individual preference for first-
line induction medications under the three clinical scenarios
(Scenarios A-C). One or multiple answers could be selected
from the following choices: Cyclophosphamide (IV or PO),
Rituximab, steroid (IV or PO), plasmapheresis, or other. After
Scenario A choices were made, respondents were asked if
their induction preferences would differ from Scenario A
when considering Scenarios B or C, and if affirmed would
prompt a follow-up set of questions with the same answer
choices. Table 2 summarizes the answer combinations and
any significant specialty differences for each scenario.
Specialty-specific differences emerged for choice of
induction agent across scenarios. Neph were more likely to
choose Cyclophosphamide for Scenario A, whereas Rheum
were more likely than Neph to use Rituximab together with
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Table 1: General characteristics of survey respondents.
Total N Rheum % Neph %
Identified as a Rheumatologist / Nephrologist 138 44.9 55.1
Experience Level 138
In practice >5 years 61.8 79.1
In practice <5 years 27.3 17.9
Fellows-in-training 10.9 3
Mid-Level Providers 0 0
Practice Setting 138
University/Tertiary care/Academic 90.9 98.5
Community Hospital / Non-teaching / Non-academic 1.8 1.5
Private Practice 7.3 0
Supervise fellows directly 136 44.4 54.5
Institution has a Pediatric Nephrology Division 138 98.2 100
Institution has a Pediatric Rheumatology Division 135 96.3 89.2
Management
Who manages pediatric GPA patients primarily at your institution? 138
Primary Rheum 44 ∗ 9.5 ∗
Primary Neph 0 ∗ 27 ∗
Co-Management 56 ∗ 63.5 ∗
Your institution does NOT have a written induction protocol 138 87.3 92.5
Your institution does NOT have a written maintenance protocol 138 90.9 97.0







∗Denotes significant difference by specialty p <0.0001.
Cyclophosphamide for both Scenarios A and B. Additionally
there was an unique specialty difference for those who stated
their induction agent would differ in Scenario C, a new
diagnosis patient with pulmonary hemorrhage.
Experience level (categorized by <5 years including fel-
lows in training, or≥ 5 years) influencedRheumresponses for
Cyclophosphamide and Rituximab in Scenario A only.Those
with relatively more practice experience (≥5 years) chose
Cyclophosphamide with more frequency (67.65% versus
23.81%, p=0.0008) and chose Rituximab with less frequency
(78.18% versus 95.24%, p=0.0120). Plasmapheresis choice
in Scenarios A-C and all other responses for Scenarios B
and C were insignificant (p>0.05) when filtered by Rheum
practice experience. There were no significant differences
related to experience in Scenarios A-C for nephrologists.
Next, induction responses were filtered for the number of
GPA patients actively followed in the practice, categorized
as 0-4 versus ≥ 5. There were no significant differences
(p>0.05) for the induction agent chosen in either specialty
when filtered by patient volume, except for Neph responses
for Rituximab in ScenarioC (pulmonary hemorrhage), where
64.29% of those with relatively higher patient volume chose
Rituximab versus 35.71% with lower volume, p=0.02.
The remaining questions in Section 2 regarding dosing
characteristics of the induction medications asked respon-
dents to frame their answers in terms of Scenario A.
3.2.1. Cyclophosphamide. The majority (65.3%) of respon-
dents chose “>3 to 6 months” as the typical duration of
induction Cyclophosphamide whereas 21.3% chose “>2 to
3 months.” The chosen interval was once per month in
78.5% whereas only 9.2% chose daily oral or every 2 weeks
IV (specialty difference p>0.05). Both Rheum and Neph
use an increasing dose protocol ending at 1000 mg/m2
(85%, p>0.05), but more Neph start at 500 mg/m2 (71.4%,
specialty difference p=0.0358) whereas 36% of Rheum start
at either 500 mg/m2 or 750 mg/m2. Conversely there was
a consensus with no specialty difference for the start-
ing dose, which was a median of 500 mg/m2, amongst
those that chose both Cyclophosphamide and Rituximab
for induction. Finally, 46.1% of respondents (specialty
difference p>0.05) routinely refer adolescent patients to
fertility specialists, whereas another 10.8% only refer if
the patient nears a maximum cumulative dose limit of
10-15 g/m2.
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Table 2: Characteristics of combination answer selections for Scenarios A-C.




Cyclophosphamide 77 ∗ 36.4 63.6 p=0.0114
+ IV/PO Steroid 71 92.2
+ Rituximab 26 ∗ 61.5 38.5 p=0.001
+ Plasmapheresis 14 19.5
+ Rituximab + Plasmapheresis 9 11.7
Rituximab without Cyclophosphamide 39 60
+ IV/PO Steroid 36 92.3




6 ∗ 0 100 p<0.0001
Scenario B
My preferences would be different than
that chosen in Scenario A
75 61.5
Cyclophosphamide 61 81.3
+ IV/PO Steroid 52 85.3
+ Rituximab 23 ∗ 65.2 34.8 p=0.0185
+ Plasmapheresis 40 65.6
+ Rituximab + Plasmapheresis 17 27.8
Rituximab without Cyclophosphamide 7 9.3
+ IV/PO Steroid 0 0
+ IV/PO Steroid + Plasmapheresis 7 100
Plasmapheresis without
Cyclophosphamide or Rituximab 6 ∗ 0 100 p<0.0001
Otheri 1 1.3
Scenario C
My preferences would be different than
that chosen in Scenario A
72 ∗ 47.2 67.7 p=0.0232
Cyclophosphamide 45 63.4
+ IV/PO Steroid 40 88.9
+ Rituximab 16 35.6
+ Plasmapheresis 40 88.9
+ Rituximab + Plasmapheresis 13 32.5
Rituximab without Cyclophosphamide 13 18.3
+ IV/PO Steroid 12 92.3
+ IV/PO Steroid + Plasmapheresis 10 83.3
Plasmapheresis without
Cyclophosphamide or Rituximab 11 13.4
Otherii 3 4.1
iOne subject chose ‘other’ but did not describe treatment in free text.
iiOne subject chose ‘other’ but did not describe treatment in free text; two did not select any option.
3.2.2. Rituximab. The method of dosing induction Ritux-
imab differed significantly by specialty in terms of duration
(p=0.0054), interval (p=0.0217), starting dose (p=0.0386),
and set maximum dose (p=0.0033). The majority of Rheum
(51.4%) dose at 750 mg/m2 every two weeks (35.1% dose at
375 mg/m2), whereas most Neph (77.8%) dose at 375 mg/m2
every four weeks. Rheum was more likely than Neph (84.6%
versus 50%) to set amaximumdose of Rituximab of 1,000mg,
whereas 50% of Neph reported no set maximum dose.
3.2.3. Steroids. The form of steroid chosen for induction
differed by specialty (p=0.0068): “IV Methylprednisolone
always” was chosen by 47.7% of Rheum and 75.9% by
Neph, whereas “IV Methylprednisolone usually, depending
International Journal of Nephrology 5
on severity” was chosen by 38.6% Rheum and 22.2% Neph.
Only 1.9% of Neph and 13.6% Rheum chose “PO steroid
usually” and none “PO steroid always.” Three days of induc-
tion IVMethylprednisolone was themost common approach
by both Rheum (89.5%) and Neph (88.5%). 92.2% overall
dose IV Methylprednisolone using a mg/kg unit up to a set
maximum amount of 1,000 mg (93.3%). Only 6 respondents
(100% Neph) chose IV steroid as the lone induction agent
for Scenario A, while none chose this as single therapy in
Scenarios B or C.
3.2.4. Plasmapheresis. While approximately 60% of respon-
dents stated their induction choice would differ in a RPGN
(Scenario B) or pulmonary hemorrhage (Scenario C) pre-
sentation versus Scenario A, there were similarities in the
proportions of Rituximab and Cyclophosphamide selections
with no difference by specialty. The difference arose in a
higher selection of plasmapheresis: in Scenarios A, B, and
C, respectively, the percentage of Rheum that chose plasma-
pheresis increased from 11.4%, 36.7%, and 51.9% versus Neph
21.4%, 42.9%, and 35.7%. Six and 11 respondents chose
plasmapheresis as the lone induction agent for Scenarios
B and C, respectively, which differed by specialty only for
Scenario B.
3.3. Survey Section 3:MaintenanceMedications. Respondents
were next asked about duration of maintenance therapy,
presuming patients remain free of relapse during that time.
Most commonly respondents chose “>18 months to 2 years”
(34.5%), followed by “>2 to 3 years” (26.7%) and “>12 to 18
months” (19.8%) with no difference by specialty (p=0.3335).
3.3.1. Steroids. 74.6% of respondents “always” use prednisone
as a part of maintenance therapy; 22.8% use it “depending
on severity of illness at presentation” (no specialty difference,
p>0.05). The duration did differ by specialty (p=0.0022):
49.1% of Rheum wean prednisone “as quickly as possible
once in remission, no set duration” versus 18% of Neph. The
next most common response was “wean off by 6 months”
(Rheum 29.1%, Neph 27.9%) and “wean off by 1 year” (Rheum
12.7%, Neph 23%). 18% of Neph versus 1.8% Rheum preferred
to “remain on prednisone for the duration of maintenance
therapy.”
3.3.2. Rituximab. 60% of Rheum versus 9.8% Neph chose
Rituximab as first-line maintenance therapy (p<0.0001). Of
note, 97% of Rheum and 60% Neph who chose Rituximab
for first-line maintenance also chose Rituximab for first-line
induction therapy (p=0.0403).The duration for maintenance
Rituximab did not differ by specialty (p=0.3967): the most
common response was “>6-12 months” (30.8%), followed by
“>24 months” (23.1%) and “>18-24 months” (20.5%). Overall
61.5% of respondents dose Rituximab at intervals of once
every 6 months, with some (25.6%) dosing it if the CD19
count rises above a set level (no specialty difference, p>0.05).
Only 9 respondents described how they use this CD19 level in
free text, and there was no consensus amongst the responses.
94.7% dose usingmg/m2 unit.Most Neph begin dosing at 375
mg/m2 (83.3%), whereas Rheum start dosing at 750 mg/m2
(44.8%), p=0.0419. A consensus maximum set dose of 1,000
mg was common amongst both groups (82.1%).
3.3.3. Azathioprine, Mycophenolate Mofetil, and Trimetho-
prim-Sulfamethoxazole. Overall 50.5% of respondents use
Azathioprine over Mycophenolate Mofetil (MMF, 38.5%)
for maintenance, and 11% overall chose “Other-not Aza-
thioprine, MMF, or Rituximab primarily for maintenance.”
While there was no difference by specialty for Azathioprine
versus MMF choice, p=0.0654, Neph chose MMF in greater
proportions than Rheum (45.8% versus 30%). Free text
options were provided by 10 out of 12 respondents who
chose “Other”: 3 reported using both Azathioprine andMMF
simultaneously, 3 use Methotrexate, 3 stated they choose
either Azathioprine or MMF situationally, and 1 misclassified
and prefers Rituximab overAzathioprine/MMF.Of those that
selected Rituximab for maintenance in the previous survey
question (n=39), 47.1% also chose Azathioprine and 35.3%
MMF with no difference by specialty (p>0.05).
The use of Trimethoprim-Sulfamethoxazole (TMP-SMX)
for either Pneumocystis jiroveci (PJP) prophylaxis or as an
additional component to maintenance therapy was next
determined and did not differ by specialty (p>0.05). Overall,
81% of respondents use TMP-SMX in some way for GPA
treatment: 37.1% of respondents use TMP-SMX purely for
PJP prophylaxis, 37.1% use it for both PJP prophylaxis and
to reduce relapse by decreasing sino-pulmonary carriage of
staphylococcus or streptococcus bacteria, and 6.9% report
using it to reduce the risk of relapse alone. The majority,
78%, do not monitor staphylococcus or streptococcus nasal
carriage by nasal swab or culture, however, 10% check once
at the start of treatment, and 12% test nasal swabs periodi-
cally. The TMP-SMX dosing interval did differ by specialty
(p=0.0006), with Neph dosing it daily (48%, Rheum 11.4%),
followed by three times a week (Neph 48%, Rheum 80%) and
least common once per day on weekends only (Neph 4%,
Rheum 9.1%).
3.4. Survey Section 4: Diagnostic Work-Up and
Disease Monitoring
3.4.1. Diagnostic Work-Up. 88.3% of Neph “always” obtain
a renal biopsy to confirm the diagnosis of GPA upon initial
presentation, versus 47.3% of Rheum (p<0.0001). The extent
of CT imaging to determine involvement of sino-pulmonary
disease at the time of GPA diagnosis did not differ by
specialty (p=0.0825). Most commonly a “LIMITED CT-scan
depending on clinical presentation” (56.5%) was chosen,
followed by “always obtain a FULL CT Head, Neck, Sinus,
andChest” (35.7%) or “no, never” (7.8%).Those that chose the
limited CT-scan optionwere asked in follow-upwhether they
“always” obtained one or multiple specific organ systems:
“head” (0%), “neck” (0%), “sinus” (Rheum 21%, Neph 79%,
p=0.0266), “chest” (Rheum 37.1%, Neph 14.5%, p=0.0022), or
“any combination of these but only if the patient has active
symptoms” (24.6% overall, p=0.4934).
3.4.2. Disease Monitoring. To define a GPA relapse, 41.2%
overall use “either clinical characteristics or serological
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marker elevation,” 35.1% use “clinical characteristics and
symptomatology only,” and 23.7% require “both clinical
and serological marker elevation simultaneously” with no
specialty difference, p>0.05. Specific diagnostic tools rou-
tinely employed included the following: ESR or CRP (Rheum
75.8%, Neph 50%, p=0.0019), ANCA titer (63.0%, p=0.1473),
hematuria and/or proteinuria (73.9%, p=0.1038), and 9.4%
(p=0.4970) use the Birmingham Vasculitis Activity Score.
Three respondents wrote in use of the Pediatric Vasculitis
Activity Score to assess relapse. The majority of respondents
monitor ANCA titers “every 3 months” (64.4%), followed
by “every 6 months” (13.9%), “only at times when a clinical
relapse is suspected” (9.6%), “other” (8.7%), or “never” (3.5%)
without specialty difference.
3.5. Survey Section 5: Management of GPA with End-Stage
Renal Disease (ESRD). The answer choices for the questions
on dialysis and ESRD management included an option
to select “unsure–I do not manage dialysis or transplant”
(Rheum > Neph as expected, p<0.0001) and are reported in
Table 3. It was expected that nearly all Rheum and someNeph
would choose this ‘unsure’ option as ESRD management
would be outside the scope of practice for some. However,
there was variability in the proportion selecting the ‘unsure’
option for each question. Next, the ‘unsure’ responses were
excluded from analysis. Once a GPA patient is declared
ESRD, the time in remission considered ‘safe’ to receive
a kidney transplant was “10-12 months” (34.7%), followed
by “4-6 months” (25.0%) and “13-18 months” (23.6%) with
no difference by specialty (p=0.2452). Although there was
specialty difference in those that stated their transplant
induction and maintenance choices would differ from non-
GPA transplant recipients, proportions of the actual medi-
cations chosen were similar between groups. The majority
(79.6%) chose anti-thymocyte globulin and IV steroid (81.5%)
for induction, while majority for maintenance was MMF
(98.2%), tacrolimus (94.5%), and PO steroid (67.3%).
4. Discussion
This survey revealed notably that, for GPA presenting with
glomerulonephritis (Scenario A), an induction preference
emerged forRheum towardsRituximab+Cyclophosphamide
and Neph towards Cyclophosphamide. The adult RAVE trial
showed noninferiority of Rituximab to Cyclophosphamide
for induction, as well as noninferiority in achieving complete
remission rates at 6, 12, or 18 months in the follow-up
RITUXVAS trial [6, 7]. However, the RAVE trial did not
include dialysis-dependent patients at the time of presenta-
tion or those with serum creatinine >4mg/dL, characteristics
that might be seen in a presentation of RPGN as with
Scenario B. No trial has compared combination therapy
(Cyclophosphamide + Rituximab) versus monotherapy for
induction to our knowledge. One possible reason for the
preferred combination is perhaps a perception of a more
severe disease in pediatric than adult patients with GPA
and glomerulonephritis. An alternative explanation is that
the combination choice may allow for a reduced dose of
Cyclophosphamide to decrease toxicity, which is suggested by
these data which showed more Rheum chose a starting dose
of 750 mg/m2 for Cyclophosphamide alone but the median
dose was 500mg/m2 for the combination Cyclophosphamide
+ Rituximab.
The percentage of those choosing induction plasma-
pheresis for Scenarios B and C (roughly 35-50%) is not as
high as would be expected if individuals follow or agree with
the EULAR recommendations, where it is stated that plasma
exchange should be considered for patients with RPGN or
pulmonary hemorrhage (Statement #6, grades of evidence
1B and C, respectively) [5]. The rationale for choosing IV
steroid as the lone induction agent for a minority of Neph
respondents is unclear, but perhaps reflects a misunderstand-
ing of the question or area for further investigation. Practice
experience level and patient volume did differ for some
induction responses, but did not have a consistent effect to
explain differences revealed by this study.
There was little consensus overall on maintenance thera-
pies or strategies; for example, no consensus emerged for the
total duration of maintenance therapy, duration of steroid,
or reason for using TMP-SMX. The overall 50% use of
Azathioprine for maintenance was lower than expected,
considering the findings of the IMPROVE [8] andWEGENT
[9] trials that showed Azathioprine is superior to MMF
or Methotrexate with fewer adverse events in adult GPA
studies. Most Rheum use Rituximab for maintenance (and
first-line induction) in line with the findings of the adult
MAINRITSAN trial [10], where Rituximab was found to be
superior for major relapses over 28 months compared to
maintenance Azathioprine. Despite the majority of Rheum
choosing Rituximab for both induction and maintenance,
there was no consensus on the total duration of maintenance
therapy revealing an area for investigation. The specialty
differences in induction and maintenance preference found
by this survey may reflect subspecialty favor of the medica-
tions based on experience with other diseases. For example,
Cyclophosphamide and MMF are commonly used in sys-
temic lupus erythematosus and other conditions and may
explain the Neph preference for these agents. Additionally,
if a provider is expecting that a GPA patient will eventually
need renal transplantation, they might choose MMF for
maintenance of GPA in planning the continuation of this
medication for maintenance after transplantation.
Finally, Section 5 of the survey revealed some areas
for consensus building but also areas that require further
investigation. Limited adult data exist on renal transplant
outcomes in GPA, and it is not clear whether the findings
in the literature can be extrapolated to pediatrics. It is not
unexpected that the rates of Rheum answering “unsure–I
do not manage dialysis or transplant” were higher than
Neph; however the absolute numbers choosing this option
varied by question in this section. This may indicate that
some rheumatologists do have practice preferences for some
ESRD/dialysis management questions but not others, and
is worth exploring in future studies. For example, 42 out
of 55 Rheum were unsure of dialysis modality choice when
considering infection risk, but only 32 out of 55 were unsure
























































































































































































































































































































































































































































































































































8 International Journal of Nephrology
whether immunosuppression should be tapered sooner than
non-dialysis GPA patients. The variance in Rheum selection
of the unsure optionmay reflect the cooperativemanagement
relationship between Neph and Rheum for these patients,
even after a patient has developed ESRD. Overall, most
respondents do not wait for ANCA to be negative at time
of transplant nor believe it influences risk of relapse which
is supported by a retrospective adult study [11]. However
25% of respondents in this survey would transplant at less
than 12 months in remission, which in the same study
was associated with graft loss. ANCA disease relapse is
reported to be low once patients are on chronic dialysis,
but rates of infectious episodes while on chronic dialysis are
high at 1.92/person-year [12, 13]. Some experts recommend
hemodialysis over peritoneal dialysis for this reason, but
no trials have specifically addressed this. Our survey did
not find a preference for hemodialysis when considering
infection risk. Lee et al. recommended from their analysis
that continued immunosuppression after 4 months in ESRD
dialysis-dependent patients is unlikely to be individually
beneficial weighing the risks and benefits [14]. While a
comprehensive study addressing the risk of infection versus
benefit of continued immunosuppression while on dialysis
has not been undertaken, the 75.6% response rate (excluding
unsure responses) that immunosuppression course would
not be shortened conflicts with the prior recommendations,
revealing an area for future study. Co-management of these
children even after ESRD is warranted based on the lack of
data and variability of practice patterns.
5. Conclusion
This survey has revealed differences in practice patterns
between specialties, with a few trends noted. Rituximab +
Cyclophosphamide is a more common induction choice for
rheumatologists than nephrologists in Scenarios A and B,
whereas Cyclophosphamide is more commonly chosen by
nephrologists in Scenario A. Plasmapheresis rates increased
for Scenarios A, B, and C for both specialties, but were
not as frequently chosen as one would expect if EULAR
recommendations were followed. Variability found in this
survey may be explained by a multitude of reasons: pediatric
GPA patients with glomerulonephritis may be perceived to
be more ill or not fit the recommendations extrapolated from
adult trials; specialists may not be familiar with the most
recent study results or recommendations as they encounter
pediatric GPA patients rarely with majority following 2-4 in
the practice; specialists may apply knowledge ofmanagement
of other conditions to management of GPA contrary to
recommendations; and the lack of evidence-based consensus
statements or clinical trials for pediatric-specific GPA leads
to varied practice patterns.
This survey has revealed important differences in the
way that rheumatologists and nephrologists manage this
disease. It has identified a need for improved dissemination
of evidence-based results to influence practice patterns and
reveals that both specialties must be represented during
consensus-building and clinical trial design efforts.This study
also underlines the need for well-designed controlled trials in
pediatric GPA patients.
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